Invited Article: Comparative effectiveness research, evidence-based medicine, and the AAN

被引:14
作者
French, Jacqueline A. [1 ]
England, John D. [2 ]
机构
[1] NYU, Comprehens Epilepsy Ctr, New York, NY USA
[2] Louisiana State Univ, Dept Neurol, Hlth Sci Ctr, Sch Med, New Orleans, LA USA
关键词
ACUTE ISCHEMIC-STROKE; RANDOMIZED CONTROLLED-TRIALS; GUILLAIN-BARRE-SYNDROME; QUALITY STANDARDS SUBCOMMITTEE; ACADEMY-OF-NEUROLOGY; AMERICAN-ACADEMY; PLASMA-EXCHANGE; PRACTICE PARAMETER; CAROTID STENOSIS; ASPIRIN;
D O I
10.1212/WNL.0b013e3181ec7f56
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Comparative effectiveness research (CER) is the study of the relative effects of treatments to determine which will be most likely to improve overall health for a specific condition. This area has received a great deal of political focus, and substantial funding for CER is included in the American Reinvestment and Recovery Act of 2009. The results of CER are intended to inform evidence-based guidelines and to improve the quality and effectiveness of medical care. In the absence of such research, guidelines often depend on consensus to rank available therapies. We believe that an increase in CER would clearly enhance evidence-based guidelines. However, the research must be performed and analyzed with great care to avoid reaching unhelpful, or even harmful, conclusions. Specifically, individual patient characteristics must be taken into account, study endpoints must approximate the most important patient outcomes, therapies must be used optimally within the studies, and the most relevant therapies for a given indication must be included for comparison. CER that is not performed or interpreted correctly could have the potential to affect negatively our choices of therapies. The neurology community must help inform the process of CER to ensure the highest-quality research, which in turn will result in the most valid outcomes. Neurology (R) 2010; 75: 562-567
引用
收藏
页码:562 / 567
页数:6
相关论文
共 29 条
  • [1] [Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000187.PUB2
  • [2] Low-molecular-weight heparins and heparinoids in acute ischemic stroke - A meta-analysis of randomized controlled trials
    Bath, PMW
    Iddenden, R
    Bath, FJ
    [J]. STROKE, 2000, 31 (07) : 1770 - 1778
  • [3] Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part I
    Berger, Marc L.
    Mamdani, Muhammad
    Atkins, David
    Johnson, Michael L.
    [J]. VALUE IN HEALTH, 2009, 12 (08) : 1044 - 1052
  • [4] Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome
    Bril, V
    Ilse, WK
    Pearce, R
    Dhanani, A
    Sutton, D
    Kong, K
    [J]. NEUROLOGY, 1996, 46 (01) : 100 - 103
  • [5] Indications for early aspirin use in acute ischemic stroke - A combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial
    Chen, ZM
    Sandercock, P
    Pan, HC
    Counsell, C
    Collins, R
    Liu, LS
    Xie, JX
    Warlow, C
    Peto, R
    [J]. STROKE, 2000, 31 (06) : 1240 - 1249
  • [6] Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis
    Chimowitz, MI
    Lynn, MJ
    Howlett-Smith, H
    Stern, BJ
    Hertzberg, VS
    Frankel, MR
    Levine, SR
    Chaturvedi, S
    Kasner, SE
    Benesch, CG
    Sila, CA
    Jovin, TG
    Romano, JG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (13) : 1305 - 1316
  • [7] Anticoagulants and antiplatelet agents in acute ischemic stroke - Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association)
    Coull, BM
    Williams, LS
    Goldstein, LB
    Meschia, JF
    Heitzman, D
    Chaturvedi, S
    Johnston, KC
    Starkman, S
    Morgenstern, LB
    Wilterdink, JL
    Levine, SR
    Saver, JL
    [J]. STROKE, 2002, 33 (07) : 1934 - 1942
  • [8] Treatment of newly diagnosed epilepsies:: the shortcomings of SANAD
    Ferrie, Colin D.
    Gruenewald, Richard A.
    Livingston, John H.
    Panayiotopoulos, Chrysostomos P.
    [J]. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2008, 50 (04) : 247 - 247
  • [9] Invited Article: Lost in a jungle of evidence We need a compass
    French, Jacqueline
    Gronseth, Gary
    [J]. NEUROLOGY, 2008, 71 (20) : 1634 - 1638
  • [10] First-choice drug for newly diagnosed epilepsy
    French, Jacqueline A.
    [J]. LANCET, 2007, 369 (9566) : 970 - 971